Developing targeted inhibitors for specific forms of Casein Kinase 1 to improve cancer treatment
Computer-aided design and development of isoform selective inhibitors of Casein Kinase 1
This study is working on developing new treatments that specifically target certain forms of a protein called Casein Kinase 1, which is important in how cells communicate and can be involved in cancer; the goal is to create more effective cancer therapies that have fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Queens College NIH-funded |
| Lab location | 1 site (Flushing, United States) |
| Project ID | NIH-11081676 on NIH RePORTER |
What this research studies
This research focuses on creating selective inhibitors for different isoforms of Casein Kinase 1 (CK1), which play crucial roles in cellular signaling and cancer development. By using advanced computational methods and synthetic chemistry, the project aims to address the challenge of off-target effects commonly seen with current cancer therapies. The goal is to enhance the specificity of these inhibitors, allowing for more effective treatment options with fewer side effects for patients. This work could lead to a better understanding of CK1's role in various diseases and improve therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are influenced by the CK1 signaling pathways.
Not a fit: Patients whose cancers are not associated with CK1 signaling or those who do not respond to kinase inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments by providing targeted therapies that minimize side effects.
How similar studies have performed: While the development of isoform-selective inhibitors is a relatively novel approach, there have been successful instances in targeting specific kinases in cancer therapy, indicating potential for success in this area.
Where this research is happening
Flushing, United States
- Queens College — Flushing, United States (Active)
Researchers
- Principal investigator: Choi, Jun-Yong — Queens College
- Study coordinator: Choi, Jun-Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.